ReviewNeurology international2023
Chronic Administration of Melatonin: Physiological and Clinical Considerations.
Review in Neurology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Pooled it
- Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.Nutrients · 2025Pooled it
- Effectiveness of Cognitive Behavioural Therapy for Insomnia (CBT-I) in Individuals With Neurodevelopmental Conditions: A Systematic Review.Journal of sleep research · 2025Pooled it
- Efficacy of clonidine and melatonin for treating insomnia in anxious children: a randomized comparison.BMC pediatrics · 2026Trial
- Lactiplantibacillus plantarum Lp815 improves sleep and increases urinary GABA in a randomized, double-blind, placebo-controlled study of sleep disturbance.Scientific reports · 2026Trial
- The effect of oral melatonin on the quality of life, sleep and blood pressure of hemodialysis patients: a randomized clinical trial.BMC nephrology · 2025Trial
- Efficacy of melatonin for prolonged disorders of consciousness: a double-blind, randomized clinical trial.BMC medicine · 2024Trial
- The Circadian-Melatonin Axis in Bone Remodeling: Receptor-Dependent Signaling, Receptor-Independent Actions, and Translational Constraints.Biomolecules · 2026Review
- Synergistic In Vitro Effects of Minor Phytocannabinoids and Melatonin Combinations Against Human Glioblastoma Cells.International journal of molecular sciences · 2026Article
- Efficacy and Safety of Sustained-Release Melatonin Capsules (2 mg) in Healthy Adults with Poor Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial.Clocks & sleep · 2026Article
- Biomarkers and Breakdowns: Neuroinflammatory Drivers Linking Sleep Disorders and Chronic Pain.Biomedicines · 2026Review
- The Pinealoprive Syndrome: Myth or Reality?Advances and technical standards in neurosurgery · 2026Review
- Rhythms of life: melatonin, nutrition, sleep, and antioxidant strategies for healthy aging.Frontiers in neuroscience · 2026Review
- Complex network model reveals the positive effect of melatonin on bone parameters in rats with induced hypoestrogenism.Bone & joint research · 2025Article
- Protective effects of melatonin and naringenin against acitretin induced hepatotoxicity via modulation of oxidative stress and inflammatory signaling.Scientific reports · 2025Article
- Protective Effect of Melatonin Against Bisphenol A Toxicity.International journal of molecular sciences · 2025Review
- Melatonin Interventions in Autism Spectrum Disorder: Sleep Regulation, Behavioral Outcomes, and Challenges Across the Lifespan.Molecular neurobiology · 2025Review
- Unveiling mysteries of aging: the potential of melatonin in preventing neurodegenerative diseases in older adults.Biogerontology · 2025Review
- Effects of Melatonin-Loaded Poly(N-vinylcaprolactam) Transdermal Gel on Sleep Quality.Gels (Basel, Switzerland) · 2025Article
- Melatonin Interplay in Physiology and Disease-The Fountain of Eternal Youth Revisited.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExogenous melatonin is commonly used to treat insomnia, other sleep problems, and numerous medical illnesses, including Alzheimer's disease, autism spectrum disorder, and mild cognitive impairment in adults and children. There is evolving information regarding issues with the use of chronic melatonin.
methodsThe present investigation was a narrative review.
resultsMelatonin usage has risen dramatically in recent years. Many countries only allow melatonin prescriptions. In the United States (U.S.), it is classified as a dietary supplement accessible over the counter and can be derived from animals, microorganisms, or, most commonly, made synthetically. No regulatory agency oversees its manufacturing or sale in the U.S. melatonin concentration of marketed preparations varies widely between product labels and manufacturers. Melatonin's ability to induce sleep is detectable. However, it is modest for most people. Sleep length appears to be less important in sustained-release preparations. The optimal dosage is unknown, and routinely used amounts vary substantially. Melatonin's short-term negative effects are minimal, resolve at medicine cessation, and do not usually prevent usage overall. Much research on long-term melatonin administration has found no difference between exogenous melatonin and placebo in terms of long-term negative effects.
conclusionMelatonin at low to moderate dosages (approximately 5-6 mg daily or less) appears safe. Long-term usage appears to benefit certain patient populations, such as those with autism spectrum disorder. Studies investigating potential benefits in reducing cognitive decline and increased longevity are ongoing. However, it is widely agreed that the long-term effects of taking exogenous melatonin have been insufficiently studied and warrant additional investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.